J Stroke Search

CLOSE


J Stroke > Volume 28(3); 2026 > Article
Gao, Wang, Ren, Zhou, Zhang, Cai, Yang, Sun, Wang, Wang, and Pan: Association Between Predicted 10-Year Atherosclerotic Cardiovascular Disease Risk and Magnetic Resonance Imaging-Defined Covert Brain Infarction
Dear Sir:
Covert brain infarction (CBI) is a clinically silent cerebrovascular
lesion that doubles the risk of future stroke and is strongly associated with cognitive decline [1-3], yet its detection depends almost exclusively on magnetic resonance imaging (MRI), which limits its feasibility for large-scale screening in asymptomatic populations. As a result, most individuals with covert cerebral ischemic injury remain unidentified until overt neurological events occur. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk score provides an integrated assessment of global vascular risk and is widely used in routine clinical practice to guide preventive care [4,5]. Although ASCVD and CBI share overlapping vascular mechanisms, ASCVD scores were originally developed to predict overt macrovascular events rather than subclinical cerebral ischemic injury detectable on neuroimaging. Whether cumulative vascular risk captured by ASCVD estimation also reflects existing subclinical cerebrovascular injury remains unclear. In this community-based study, we investigated the association between 10-year ASCVD risk estimated by the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations and MRI-defined CBI in stroke-free middle-aged and older adults.
This cross-sectional analysis was conducted within the community-based PRECISE (PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events) study (ClinicalTrials.gov NCT03178448), which enrolled 3,067 adults aged 50-75 years from urban and rural communities in China. Standardized interviews, physical examinations, and laboratory testing were performed at baseline [6]. The study protocol was approved by the ethics committees of Beijing Tiantan Hospital (KY2017-010-01) and Lishui Central Hospital (2016-42), and all participants provided written informed consent. The 10-year ASCVD risk was estimated using the PREVENT equations, including the base, urine albumin-creatinine ratio (UACR), and hemoglobin A1c (HbA1c) models. Participants were categorized into four risk strata (<5.0%, 5.0%-7.4%, 7.5%-19.9%, and ≥20.0%). The PREVENT-base equation includes routinely collected clinical predictors, including age, sex, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, body mass index, estimated glomerular filtration rate, history of diabetes, smoking status, and use of antihypertensive or lipid-lowering medications. The PREVENT-UACR equation additionally includes UACR, and the PREVENT-HbA1c equation additionally includes HbA1c. Risk categories were defined according to commonly used 10-year ASCVD risk thresholds for clinical risk stratification. All participants underwent 3.0 T brain MRI using a standardized protocol, and CBI was centrally assessed by blinded neuroradiologists according to the Standards for Reporting Vascular Changes on Neuroimaging 2 criteria [7]. Multivariable logistic regression models, adjusted for clinically relevant covariates not directly incorporated in the PREVENT equations, were used to evaluate associations between PREVENT risk categories and CBI and its imaging phenotypes, with restricted cubic spline analyses applied to explore nonlinear relationships. Detailed MRI acquisition parameters for each sequence are provided in Supplementary Table 1 and imaging criteria for each imaging phenotype are provided in Supplementary Table 2, with their corresponding imaging examples shown in Supplementary Figure 1. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R version 4.6.0 (R Foundation for Statistical Computing, Vienna, Austria).
After excluding individuals with prior stroke or transient ischemic attack (TIA) and those with incomplete imaging data, 2,965 participants were included (Supplementary Figure 2). Among the included participants (mean age 61.05 years; 46.17% men), 284 (9.58%) had MRI-defined CBI. Participants with CBI were older and had a higher burden of vascular risk factors. Baseline characteristics by CBI status are summarized in Table 1. CBI prevalence increased from the low-risk through the borderline- and intermediate-risk categories across all three PREVENT equations. In the PREVENT-base model, CBI prevalence was 5.60%, 9.55%, and 16.67% in the low-, borderline-, and intermediate-risk groups, respectively. The high-risk groups were small (PREVENT-base, n=11; PREVENT-UACR, n=42; PREVENT-HbA1c, n=24), and estimates in these groups should therefore be interpreted cautiously (Supplementary Table 3). Similar gradients were observed in the PREVENT-UACR and PREVENT-HbA1c models (Supplementary Table 3).
In multivariable logistic regression models, higher PREVENT-ASCVD risk was shown to be associated with increased odds of CBI. Using the low-risk group as reference, the adjusted odds ratios (95% confidence intervals [CIs]) for the borderline- and intermediate-risk categories were 1.64 (1.16-2.32) and 2.97 (2.21-4.00) in the base model, 1.69 (1.19-2.39) and 2.65 (1.96-3.57) in the UACR model, and 1.69 (1.20-2.39) and 2.97 (2.20-4.01) in the HbA1c model, respectively. Associations for the borderline-and intermediate-risk categories remained statistically significant after adjustment for current drinking status, homocysteine levels, chronic lung disease, tumor history, and educational attainment across all three PREVENT models. In the high-risk category, the association remained significant in the PREVENT-UACR model, whereas estimates were not statistically significant in the PREVENT-base and PREVENT-HbA1c models (Figure 1 and Supplementary Table 3). In sensitivity analyses using an alternative PREVENT risk categorization, the association between higher PREVENT-estimated ASCVD risk and MRI-defined CBI remained materially unchanged (Supplementary Table 4). Restricted cubic spline analyses demonstrated a nonlinear association between continuous PREVENT-ASCVD risk and CBI prevalence (Figure 2). The increase in CBI odds was particularly steep when the estimated 10-year ASCVD risk was below approximately 10%, after which the curve attenuated. This suggests that individuals traditionally considered at “low-to-moderate” cardiovascular risk may already carry a substantial burden of covert cerebrovascular injury. Similar graded associations were observed across CBI imaging phenotypes. As shown in Supplementary Table 5, participants in the intermediate-risk group had more than twofold higher odds of chronic infarctions and over threefold higher odds of cavitatory lesions. Although acute infarctions were infrequent, a consistent upward trend was observed across risk categories. These findings demonstrate that global cardiovascular risk estimated by the PREVENT equations is closely associated with covert cerebrovascular injury detectable by MRI. The consistency of associations across imaging phenotypes further supports the link between systemic vascular risk and subclinical cerebral ischemia.
Many established determinants of CBI, including advanced age, hypertension, diabetes, dyslipidemia, and elevated homocysteine, overlap with major components of ASCVD risk, suggesting shared pathways of chronic vascular injury [8,9]. Previous studies have linked traditional cardiovascular risk scores to MRI markers of cerebral small vessel disease [10,11]. Previous work from the PRECISE cohort showed that conventional 10-year ASCVD risk scores, including the FRS, PCE, China-PAR, and SCORE2, were associated with CSVD burden and individual MRI markers [12]. The present study extends this work by focusing on the more recently developed PREVENT equations and MRI-defined CBI and its imaging phenotypes in participants without a prior history of stroke or TIA, which provides complementary evidence linking contemporary cardiovascular risk estimation with MRI-defined covert brain infarction.
From a clinical perspective, these findings have important implications. Because CBI is typically identified only through neuroimaging yet confers substantial risk for future stroke and cognitive decline, PREVENT-based risk assessment may provide a practical framework for understanding the overlap between systemic cardiovascular risk and covert cerebrovascular injury. Among the three models, the PREVENT base equation may be the most readily applicable in routine practice because it relies on routinely collected variables. The comparable associations across the PREVENT-base, PREVENT-UACR, and PREVENT-HbA1c equations may reflect that the base equation already incorporates major CBI-related vascular risk factors, including age, blood pressure, lipid measurements, body mass index, kidney function, diabetes, smoking status, and relevant medication use. Thus, UACR and HbA1c may have provided limited additional information for CBI risk stratification in this community-based sample, possibly because of overlap with cardiometabolic variables already included in the base equation. Future longitudinal and comparative studies are needed to determine whether PREVENT-based cardiovascular risk assessment provides incremental clinical or predictive value over conventional cardiovascular risk scores for CBI. This study is limited by its cross-sectional design, single-region population, and absence of direct predictive-performance comparisons between PREVENT and traditional risk scores; therefore, it cannot establish the incremental clinical or predictive value of PREVENT for identifying CBI. Nevertheless, the integration of a contemporary ASCVD risk model with standardized MRI assessment in a community-based cohort provides novel evidence linking global cardiovascular risk and covert cerebral ischemic injury.
In summary, higher PREVENT-estimated ASCVD risk was associated with an increased likelihood of CBI in asymptomatic adults, supporting a close association between global cardiovascular risk and covert cerebrovascular injury.

Supplementary materials

Supplementary materials related to this article can be found online at https://doi.org/10.5853/jos.2026.00766.
Supplementary Table 1.
MRI parameters of the PRECISE study
jos-2026-00766-Supplementary-Table-1.pdf
Supplementary Table 2.
Imaging criteria for imaging phenotypes of covert brain infarction
jos-2026-00766-Supplementary-Table-2.pdf
Supplementary Table 3.
Associations between PREVENT-ASCVD risk scores categories and the presence of CBI
jos-2026-00766-Supplementary-Table-3.pdf
Supplementary Table 4.
Associations between revised PREVENT-ASCVD risk scores categories and the presence of CBI
jos-2026-00766-Supplementary-Table-4.pdf
Supplementary Table 5.
Associations between PREVENT-ASCVD risk scores categories and the presence of CBI imaging phenotypes
jos-2026-00766-Supplementary-Table-5.pdf
Supplementary Figure 1.
Imaging phenotypes of covert brain infarction. The arrows indicate representative lesions of the corresponding covert brain infarction imaging phenotypes. (A) Cavitatory infarction on FLAIR. (B) Acute cerebral infarction on DWI. (C) Chronic infarction: combined gray and white matter lesions on T2-weighted and FLAIR images. (D) Chronic infarction: large subcortical non-cavitated infarcts on FLAIR images. FLAIR, fluid-attenuated inversion recovery; DWI, diffusion weighted imaging.
jos-2026-00766-Supplementary-Figure-1.pdf
Supplementary Figure 2.
Flowchart of participant selection. PRECISE, PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events; CBI, covert brain infarction; TIA, transient ischemic attack.
jos-2026-00766-Supplementary-Figure-2.pdf

Notes

Funding statement
This work was supported by grants from Beijing High-level Public Health Technical Personnel Construction Project (Discipline leader-03-12), Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0504800, 2023ZD0504801, 2023ZD0504802, 2023ZD0504803, 2023ZD0504804), and grants from AstraZeneca Investment (China) Co., Ltd.
Conflicts of interest
The authors have no financial conflicts of interest.
Author contribution
Conceptualization: Peiyuan Gao, Yilong Wang, Yuesong Pan. Study design: Peiyuan Gao, Yilong Wang, Yuesong Pan. Methodology: Peiyuan Gao, Yilong Wang, Yuesong Pan. Data acquisition: Xuan Wang, Lijie Ren, Mengyuan Zhou, Ruinan Zhang, Xueli Cai, Yingying Yang, Jingping Sun, Yuesong Pan. Statistical analysis: Peiyuan Gao. Supervision: Yilong Wang, Yuesong Pan. Writing—original draft: Peiyuan Gao. Writing—review & editing: all authors. Approval of final manuscript: all authors.
Acknowledgments
The authors thank the staff and participants of the PRECISE study for their important contributions.
Deidentified participant data and statistical analysis codes are available from the PRECISE study coordinating center upon reasonable request to the corresponding author.

Figure 1.
Adjusted OR with 95% CI for presence of CBI according to PREVENT-ASCVD risk score categories. OR for presence of CBI according to PREVENT-ASCVD risk scores categories adjusted for education, drinking, level of homocysteine, history of chronic lung disease and cancer. OR and 95% CI (vertical bars) are shown for the borderline, intermediate, and high-risk groups, with the low-risk group as reference. The scores from all three models of PREVENT-ASCVD (base, UACR and HbA1c) were categorized as low (<5.0%), borderline (5.0%-7.4%), intermediate (7.5%-19.9%) or high (≥20.0%) risk. (A) PREVENT-base model. (B) PREVENT-UACR model. (C) PREVENT-HbA1c model. OR, odds ratio; CI, confidence interval; CBI, covert brain infarction; PREVENT, the Predicting Risk of Cardiovascular Disease EVENTs; ASCVD, atherosclerotic cardiovascular disease; UACR, urine albumin-creatinine ratio; HbA1c, hemoglobin A1c.
jos-2026-00766f1.jpg
Figure 2.
Association between PREVENT-ASCVD risk scores and overall CBI risk. (A) PREVENT-base model, incorporating traditional cardiovascular risk factors. (B) PREVENT-UACR model, which additionally includes UACR. (C) PREVENT-HbA1c model, which additionally includes glycated hemoglobin (HbA1c). The diagram presents ORs as solid lines and 95% CIs as shaded areas obtained from restricted cubic spline regressions. The histograms show the density distribution of PREVENT risk values and correspond to the right y-axis. The dashed line at OR 1.0 serves as the reference. Data were fitted using logistic regression models with restricted cubic spline with 3 knots (the 10th, 50th, and 90th percentiles) for PREVENT-ASCVD risk, adjusting for education, drinking, level of homocysteine, history of chronic lung disease and cancer. P for overall and P for nonlinear were derived from this model. OR, odds ratio; CI, confidence interval; PREVENT, the Predicting Risk of Cardiovascular Disease EVENTs; UACR, urine albumin-creatinine ratio; HbA1c, hemoglobin A1c; ASCVD, atherosclerotic cardiovascular disease; CBI, covert brain infarction.
jos-2026-00766f2.jpg
Table 1.
Baseline characteristics for presence or absence of CBI
Variables
CBI
P
Total (n=2,965) Absence (n=2,681) Presence (n=284)
Demographic data
 Age (yr) 61.05±6.62 60.72±6.52 64.20±6.76 <0.001
 Male sex 1,369 (46.17) 1,222 (45.58) 147 (51.76) 0.052
 Current smoking 610 (20.57) 542 (20.22) 68 (23.94) 0.143
 Current drinking 560 (18.89) 500 (18.65) 60 (21.13) 0.301
 Education 0.010
  Below high school 2,211 (74.57) 1,981 (73.89) 230 (80.99)
  High school 567 (19.12) 525 (19.58) 42 (14.79)
  Above high school 187 (6.31) 175 (6.53) 12 (4.23)
 WC (cm) 86.50 (80.00-93.00) 86.00 (80.00-93.00) 88.00 (81.00-94.50) 0.020
 BMI (kg/m2) 23.59 (21.64-25.64) 23.53 (21.64-25.61) 23.83 (21.64-26.09) 0.088
Laboratory data
 SBP (mm Hg) 128.00 (117.50-139.00) 127.50 (117.00-138.50) 134.25 (123.50-142.50) <0.001
 DBP (mm Hg) 75.00 (69.00-81.00) 74.50 (69.00-80.50) 76.50 (71.50-82.75) <0.001
 Total cholesterol (mmol/L) 5.24 (4.63-5.91) 5.23 (4.63-5.90) 5.26 (4.63-6.09) 0.375
 HDL-C (mmol/L) 1.32 (1.13-1.57) 1.33 (1.13-1.57) 1.31 (1.14-1.55) 0.535
 LDL-C (mmol/L) 2.74 (2.26-3.28) 2.73 (2.25-3.26) 2.89 (2.35-3.45) 0.005
 Homocysteine (μmol/L) 10.70 (8.90-13.10) 10.70 (8.90-12.90) 11.05 (9.10-14.55) 0.003
 eGFR (mL/min/1.73 m2) 95.03 (87.66-100.43) 95.44 (88.15-100.56) 91.41 (84.96-97.81) <0.001
 UACR (mg/g) 11.00 (7.00-22.00) 11.00 (7.00-21.00) 12.00 (8.00-27.00) 0.004
 HbA1c (%) 5.70 (5.50-6.10) 5.70 (5.50-6.00) 5.80 (5.50-6.20) 0.015
Medical history
 Hypertension 1,242 (41.89) 1,070 (39.91) 172 (60.56) <0.001
 Diabetes 629 (21.21) 550 (20.51) 79 (27.82) 0.006
 Chronic lung disease 111 (3.74) 98 (3.66) 13 (4.58) 0.412
 Cancer 375 (12.65) 351 (13.09) 24 (8.45) 0.024
Concomitant medication
 Antihypertensive 760 (25.63) 646 (24.10) 114 (40.14) <0.001
 Lipid lowering 99 (3.34) 84 (3.13) 15 (5.28) 0.079
 Antidiabetic 253 (8.53) 215 (8.02) 38 (13.38) 0.004
 Antiplatelet 59 (1.99) 52 (1.94) 7 (2.46) 0.503
 Anticoagulants 2 (0.07) 2 (0.07) 0 (0.00) NA
PREVENT-ASCVD risk
 Base model (%) 5.01 (2.91-8.05) 4.79 (2.80-7.64) 7.33 (4.52-10.94) <0.001
 UACR model (%) 5.00 (2.88-8.28) 4.76 (2.80-7.86) 7.27 (4.64-11.22) <0.001
 HbA1c model (%) 4.98 (2.96-7.91) 4.77 (2.83-7.61) 7.21 (4.50-10.75) <0.001
Values are presented as mean±standard deviation, n (%), or median (interquartile range). The base PREVENT model includes predictors such as age, sex, total cholesterol, HDL-C, SBP, BMI, eGFR, history of diabetes, smoking status, and use of antihypertensive or lipid-lowering medications. The UACR model adds UACR as an additional predictor. The HbA1c model adds HbA1c as an additional predictor.
CBI, covert brain infarction; WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; UACR, urine albumin-creatinine ratio; HbA1c, hemoglobin A1c; PREVENT, the Predicting Risk of Cardiovascular Disease EVENTs; ASCVD, atherosclerotic cardiovascular disease; NA, not applicable.

References

1. Gupta A, Giambrone AE, Gialdini G, Finn C, Delgado D, Gutierrez J, et al. Silent brain infarction and risk of future stroke: a systematic review and meta-analysis. Stroke 2016;47:719-725.
crossref pmid pmc
2. Chen DW, Wang YX, Shi J, Zhang WQ, Yang F, Yin YW, et al. Multiple silent brain infarcts are associated with severer stroke in patients with first-ever ischemic stroke without advanced leukoaraiosis. J Stroke Cerebrovasc Dis 2017;26:1988-1995.
crossref pmid
3. Lei C, Deng Q, Li H, Zhong L. Association between silent brain infarcts and cognitive function: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2019;28:2376-2387.
crossref pmid
4. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation 2024;149:430-449.
crossref pmid
5. Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation 2023;148:1982-2004.
crossref pmid
6. Pan Y, Jing J, Cai X, Wang Y, Wang S, Meng X, et al. PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)-a population-based prospective cohort study: rationale, design and baseline participant characteristics. Stroke Vasc Neurol 2021;6:145-151.
crossref pmid
7. Duering M, Biessels GJ, Brodtmann A, Chen C, Cordonnier C, de Leeuw FE, et al. Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol 2023;22:602-618.
crossref pmid
8. Zhang R, Yao D, Cai X, Zhang Y, Yang Y, Li S, et al. Prevalence and risk factors of covert brain infarction: a community-based cross-sectional study. Int J Stroke 2025;20:611-622.
crossref pmid pdf
9. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 2014;5:927-946.

10. Anand SS, Tu JV, Desai D, Awadalla P, Robson P, Jacquemont S, et al. Cardiovascular risk scoring and magnetic resonance imaging detected subclinical cerebrovascular disease. Eur Heart J Cardiovasc Imaging 2020;21:692-700.
crossref pmid pmc pdf
11. Das RR, Seshadri S, Beiser AS, Kelly-Hayes M, Au R, Himali JJ, et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke 2008;39:2929-2935.
crossref pmid pmc
12. Liu D, Zhang Y, Cai X, Yang Y, Wang S, Mei L, et al. Associations of 10-year atherosclerotic cardiovascular disease risk scores with cerebral small vessel disease: the PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE) study. Age Ageing 2024;53:afae161.
crossref pmid pdf


ABOUT JoS
AUTHOR INFORMATION
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
Editorial Office
Department of Neurology, Asan Medical Center,Ulsan University College of Medicine
88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Submission, status and progress, etc ⟫ E-mail: editor@j-stroke.org
Website and system ⟫ E-mail: support@m2-pi.com
Publishing company ⟫ E-mail: ka72sus@smileml.com
Developed in M2PI
Copyright © 2026 by Korean Stroke Society.
Close layer
prev next